<-bsp-bb-link state=”{“bbHref”:”bbg://securities/3413Z%20GR%20Equity”,”_id”:”0000018b-d295-de26-a7ef-feb543020000″,”_type”:”0000016b-944a-dc2b-ab6b-d57ba1cc0000″}”>Germany-bsp-bb-link> is considering an export ban on Novo Nordisk A/S’s blockbuster weight-loss drugs as European countries try to protect supplies amid a global shortage.

The craze around two <-bsp-bb-link state=”{“bbHref”:”bbg://securities/NOVOB%20DC%20Equity/FA”,”_id”:”0000018b-d295-de26-a7ef-feb543030000″,”_type”:”0000016b-944a-dc2b-ab6b-d57ba1cc0000″}”>Novo-bsp-bb-link> drugs that can help people shed about 15% of their weight is causing scarcity for the original patients they were intended for: people with diabetes.

Some supplies of the drugs, which are cheaper in Germany than elsewhere, get sent to other European countries and to the US, Karl Broich, president of the German Federal Institute for Drugs and Medical Devices, said in an interview with Der Spiegel magazine.

Broich’s …